Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

60.71USD
9:55am EST
Change (% chg)

$0.58 (+0.97%)
Prev Close
$60.12
Open
$60.49
Day's High
$60.78
Day's Low
$60.45
Volume
287,568
Avg. Vol
3,208,091
52-wk High
$65.45
52-wk Low
$47.97

Select another date:

Thu, Dec 1 2016

Merck wins UK okay for Keytruda in lung cancer after price cut

LONDON Britain's healthcare cost-effectiveness watchdog NICE has recommended use of Merck's immunotherapy drug Keytruda in certain lung cancer patients, after the U.S. drugmaker cut the price further for the state-run health service.

BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda

* FDA grants priority review to Merck's supplemental biologics license application (SBLA) seeking approval for Keytruda(pembrolizumab) for new indication in microsatellite instability-high cancer Source text for Eikon: Further company coverage:

Gilead, Merck to face off before jury over hepatitis C drug patents

Early next month, Gilead Sciences Inc will try to convince a federal jury in Delaware that a Merck & Co patent on hepatitis C drugs is invalid.

BRIEF-Merck raises quarterly dividend to $0.47/share from $0.46/share

* Increased quarterly dividend to $0.47 per share, up $0.01 from $0.46 per outstanding share paid last quarter Source text for Eikon: Further company coverage:

Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial

Gilead Sciences Inc has lost a bid to invalidate two Merck & Co patents on hepatitis C treatments, which Merck claims are infringed by Gilead's blockbuster Harvoni and Sovaldi.

BRIEF-Merck sees continued price pressure for Erbitux in the EU

* CEO says price pressure and competition for Erbitux in the EU will continue Further company coverage:

BRIEF-OpGen collaborates with Merck to develop rapid diagnostics and informatics tools to help combat antimicrobial resistance

* OpGen Inc - entered into research collaboration with Merck to develop rapid diagnostics, it products to help combat threat of antimicrobial resistance Source text for Eikon: Further company coverage:

BRIEF-Biothera Pharma's announces new preclinical data on its immunotherapy drug

* Biothera Pharmaceuticals' preclinical data further validate mechanism of its Phase 2 cancer immunotherapy, Imprime PGG

Correction: Fitch Rates Merck's Euro Notes Offering 'A'

(The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) (This is a correction of a release issued Oct. 27, 2016. It clarifies that Merck's existing ratings were not affirmed as was stated in the original release.) Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently intr

Fitch Rates Merck's Euro Notes Offering 'A'

(The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies, an advancing pipeline and manageable patent expiries should support intermediate- to long-term growth. --Fitch believes that Merck will pursu

Select another date: